山东省医学会肺癌多学科规范化诊疗指南

摘要/Abstract

山东省医学会肺癌多学科联合委员会. 山东省医学会肺癌多学科规范化诊疗指南[J]. 国际肿瘤学杂志, 2021, 48(5): 257-274.

参考文献74

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338. doi:10.3322/caac.21338
[2]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 can-cers from 322 population-based registries in 71 countries[J]. Lancet, 2018,391(10125):1023-1075. DOI: 10.1016/S0140-6736(17)33326-3. doi:S0140-6736(17)33326-3pmid:29395269
[3]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005.
[4]	中国肺癌防治联盟, 中华医学会呼吸病学分会肺癌学组, 中国医师协会呼吸医师分会肺癌工作委员会. 肺癌筛查与管理中国专家共识[J]. 国际呼吸杂志, 2019,39(21):1604-1615. DOI: 10.3760/cma.j.issn.1673-436X.2019.21.002.
[5]	周清华, 范亚光, 王颖, 等. 中国肺癌低剂量螺旋CT筛查指南(2018年版)[J]. 中国肺癌杂志, 2018,21(2):67-75. DOI: 10.3779/j.issn.1009-3419.2018.02.01.
[6]	MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner society 2017[J]. Radiology, 284(1):228-243. DOI: 10.1148/radiol.2017161659. doi:10.1148/radiol.2017161659
[7]	Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification[J]. Chest, 2017,151(1):193-203. DOI: 10.1016/j.chest.2016.10.010. doi:S0012-3692(16)60780-8pmid:27780786
[8]	Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart[J]. J Thorac Oncol, 2015,10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663. doi:10.1097/JTO.0000000000000663
[9]	中华医学会病理学分会胸部疾病学组. 早期(非黏液型附壁生长方式)肺腺癌冷冻切片病理诊断专家共识[J]. 中华病理学杂志, 2019,48(1):3-10. DOI: 10.3760/cma.j.issn.0529-5807.2019.01.002.
[10]	肺神经内分泌肿瘤病理诊断共识专家组. 肺神经内分泌肿瘤病理诊断共识[J]. 中华病理学杂志, 2017,46(1):9-13. DOI: 10.3760/cma.j.issn.0529-5807.2017.01.003.
[11]	刘标, 周晓军. 非小细胞肺癌免疫组化标志物专家共识(2014)[J]. 临床与实验病理学杂志, 2015,31(5):481-487. DOI: 10.13315/j.cnki.cjcep.2015.05.001.
[12]	中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组. 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J] 中华病理学杂志, 2016,45(4):217-220. DOI: 10.3760/cma.j.issn.0529-5807.2016.04.001.
[13]	中国非小细胞肺癌ALK检测模式真实世界多中心研究专家组, 中华医学会病理学分会分子病理学组. 中国非小细胞肺癌ALK检测临床实践专家共识[J]. 中华病理学杂志, 2019,48(12):913-920. DOI: 10.3760/cma.j.issn.0529-5807.2019.12.001.
[14]	中国抗癌协会病理专业委员会肺癌学组. ROS1阳性非小细胞肺癌诊断病理专家共识[J]. 中华病理学杂志, 2018,47(4):248-251. DOI: 10.3760/cma.j.issn.0529-5807.2018.04.004.
[15]	中国抗癌协会肿瘤病理专业委员会, 中国临床肿瘤学会肿瘤病理专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会. 非小细胞肺癌专家委员会中国非小细胞肺癌PD-L1表达检测临床病理专家共识[J]. 中华肿瘤杂志, 2020,42(7):513-521. DOI: 10.3760/cma.j.cn112152-20200313-00202.
[16]	Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiothe-rapy versus lobectomy for operable stage Ⅰ non-small-cell lung can-cer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015,16(6):630-637. DOI: 10.1016/S1470-2045(15)70168-3. doi:10.1016/S1470-2045(15)70168-3
[17]	Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer[J]. N Engl J Med, 2004,350(4):351-360. DOI: 10.1056/NEJMoa031644. doi:10.1056/NEJMoa031644
[18]	Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018,379(24):2342-2350. DOI: 10.1056/NEJMoa1809697. doi:10.1056/NEJMoa1809697
[19]	Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010,28(13):2181-2190. DOI: 10.1200/JCO.2009.26.2543. doi:10.1200/JCO.2009.26.2543
[20]	Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer: rando-mized phase Ⅲ trial RTOG 9410[J]. J Natl Cancer Inst, 2011,103(19):1452-1460. DOI: 10.1093/jnci/djr325. doi:10.1093/jnci/djr325
[21]	Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)[J]. J Clin Oncol, 2007,25(3):313-318. DOI: 10.1200/JCO.2006.08.2826. doi:10.1200/JCO.2006.08.2826
[22]	Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017,376(7):629-640. DOI: 10.1056/NEJMoa1612674. doi:10.1056/NEJMoa1612674
[23]	Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017,377(9):829-838. DOI: 10.1056/NEJMoa1704795. doi:10.1056/NEJMoa1704795
[24]	Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014,370(13):1189-1197. DOI: 10.1056/NEJMoa1311107. doi:10.1056/NEJMoa1311107
[25]	Wu YL, Yang JC, Kim DW, et al. Phase Ⅱ study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018,36(14):1405-1411. DOI: 10.1200/JCO.2017.75.5587. doi:10.1200/JCO.2017.75.5587
[26]	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019,393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. doi:10.1016/S0140-6736(18)32409-7
[27]	Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018,378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. doi:10.1056/NEJMoa1801005
[28]	Verma V, Simone CB 2nd, Allen PK, et al. Outcomes of stereotactic body radiotherapy for T₁-T₂N₀small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis[J]. Clin Lung Cancer, 2017, 18(6): 675-681.e1. DOI: 10.1016/j.cllc.2017.03.009. doi:10.1016/j.cllc.2017.03.009
[29]	Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial[J]. Lancet Oncol, 2009,10(5):467-474. DOI: 10.1016/S1470-2045(09)70101-9. doi:10.1016/S1470-2045(09)70101-9
[30]	Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002,346(2):85-91. DOI: 10.1056/NEJMoa003034. doi:10.1056/NEJMoa003034
[31]	Horn L, Mansfield A, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018,379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. doi:10.1056/NEJMoa1809064
[32]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019,394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. doi:S0140-6736(19)32222-6pmid:31590988
[33]	王俊. 胸腔镜外科学[M]. 北京: 人民卫生出版社, 2017.
[34]	陈亮, 朱全. 全胸腔镜解剖性肺段切除手术图谱[M]. 南京: 东南大学出版社, 2015.
[35]	Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T₁N₀non-small cell lung cancer. Lung Cancer Study Group[J]. Ann Thorac Surg, 1995, 60(3): 615-622; discussion 622-623. DOI: 10.1016/0003-4975(95)00537-u. pmid:7677489
[36]	Zhang Y, Sun Y, Wang R, et al. Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage Ⅰ non-small cell lung cancer[J]. J Surg Oncol, 2015,111(3):334-340. DOI: 10.1002/jso.23800. doi:10.1002/jso.23800pmid:25322915
[37]	庄心良, 曾因明, 陈伯銮. 现代麻醉学[M]. 北京: 人民卫生出版社, 2003.
[38]	孙玉鹗. 胸外科手术学[M]. 北京: 人民军医出版社, 2004.
[39]	Veronesi G, Galetta D, Maisonneuve P, et al. Four-arm robotic lobectomy for the treatment of early-stage lung cancer[J]. J Thorac Cardiovasc Surg, 2010,140(1):19-25. DOI: 10.1016/j.jtcvs.2009.10.025. doi:10.1016/j.jtcvs.2009.10.025
[40]	Liu L, Mei J, Pu Q, et al. Thoracoscopic bronchovascular double sleeve lobectomy for non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2014,46(3):493-495. DOI: 10.1093/ejcts/ezu103. doi:10.1093/ejcts/ezu103
[41]	姜格宁, 陈昶, 朱余明, 等. 上海市肺科医院磨玻璃结节早期肺腺癌的诊疗共识(第一版)[J]. 中国肺癌杂志, 2018,21(3):147-159. DOI: 10.3779/j.issn.1009-3419.2018.03.05.
[42]	周晓红, 唐力, 齐亚灵. 放射性肺炎的预防及治疗研究进展[J]. 医学美学美容, 2014(5):680-682.
[43]	张春伟, 金世柱, 李全晓, 等. 放射性食管炎的临床研究现状[J]. 现代生物医学进展, 2017,17(33):6589-6592. DOI: 10.13241/j.cnki.pmb.2017.33.043.
[44]	Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ non-small-cell lung cancer: a phase Ⅲ randomised controlled trial[J]. Lancet, 2009,374(9687):379-386. DOI: 10.1016/S0140-6736(09)60737-6. doi:10.1016/S0140-6736(09)60737-6pmid:19632716
[45]	Brock MV, Hooker CM, Syphard JE, et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come[J]. J Thorac Cardiovasc Surg, 2005,129(1):64-72. DOI: 10.1016/j.jtcvs.2004.08.022. doi:10.1016/j.jtcvs.2004.08.022
[46]	Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase Ⅱ trial of postope-rative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ-Ⅲa small cell lung cancer: the Japan Clinical Onco-logy Lung Cancer Study Group Trial (JCOG9101)[J]. J Thorac Cardiovasc Surg, 2005,129(5):977-983. DOI: 10.1016/j.jtcvs.2004.05.030. doi:10.1016/j.jtcvs.2004.05.030
[47]	Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial[J]. Lancet Oncol, 2006,7(9):719-727. DOI: 10.1016/S1470-2045(06)70804-X. doi:10.1016/S1470-2045(06)70804-X
[48]	Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2013,31(23):2895-2902. DOI: 10.1200/JCO.2012.47.1102. doi:10.1200/JCO.2012.47.1102
[49]	Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase Ⅲ study addressing the case for cisplatin[J]. Ann Oncol, 2005,16(4):602-610. DOI: 10.1093/annonc/mdi126. pmid:15741225
[50]	Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease[J]. Ann Oncol, 2014,25(8):1475-1484. DOI: 10.1093/annonc/mdu123. doi:10.1093/annonc/mdu123
[51]	Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017,18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. doi:10.1016/S1470-2045(17)30608-3
[52]	Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Ann Oncol, 2020,31(8):1056-1064. DOI: 10.1016/j.annonc.2020.04.478. doi:10.1016/j.annonc.2020.04.478
[53]	Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater[J]. J Clin Oncol, 2019,37(7):537-546. DOI: 10.1200/JCO.18.00149.
[54]	Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage ⅠB-ⅢA non-small-cell lung can-cer (RADIANT): a randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2015,33(34):4007-4014. DOI: 10.1200/JCO.2015.61.8918. doi:10.1200/JCO.2015.61.8918
[55]	Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019,20(5):625-635. DOI: 10.1016/S1470-2045(19)30035-X. doi:10.1016/S1470-2045(19)30035-X
[56]	Spigel DR, Hainsworth JD, Joseph MJ, et al. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage ⅢB/Ⅳ non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2[J]. Cancer, 2018,124(9):1982-1991. DOI: 10.1002/cncr.30986. doi:10.1002/cncr.30986pmid:29451696
[57]	Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer[J]. J Clin Oncol, 2021: JCO2003025. DOI: 10.1200/JCO.20.03025.
[58]	Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020,21(2):261-270. DOI: 10.1016/S1470-2045(19)30690-4. doi:10.1016/S1470-2045(19)30690-4
[59]	West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019,20(7):924-937. DOI: 10.1016/S1470-2045(19)30167-6. doi:10.1016/S1470-2045(19)30167-6
[60]	Zhao S, Li X, Zhao C, et al. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M[J]. Lung Cancer, 2019,128:33-39. DOI: 10.1016/j.lungcan.2018.12.010. doi:S0169-5002(18)30696-2pmid:30642450
[61]	Cheng Y, Fan Y, Liu X, et al. Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer[J]. Oncol Lett, 2019,17(5):4701-4709. DOI: 10.3892/ol.2019.10125. doi:10.3892/ol.2019.10125pmid:30988825
[62]	Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies[J]. J Thorac Oncol, 2020,15(4):618-627. DOI: 10.1016/j.jtho.2019.12.109. doi:10.1016/j.jtho.2019.12.109
[63]	Jie B, Jiang ZM, Nolan MT, et al. Impact of nutritional support on clinical outcome in patients at nutritional risk: a multicenter, prospective cohort study in Baltimore and Beijing teaching hospitals[J]. Nutrition, 2010,26(11-12):1088-1093. DOI: 10.1016/j.nut.2009.08.027. doi:10.1016/j.nut.2009.08.027
[64]	Zhang H, Wang Y, Jiang ZM, et al. Impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: a prospective cohort study with propensity score mathing[J]. Nutrition, 2017,37:53-59. DOI: 10.1016/j.nut.2016.12.004. doi:S0899-9007(16)30278-7pmid:28359363
[65]	中国抗癌协会, 中国抗癌协会肿瘤营养与支持专业委员会, 中国抗癌协会癌症康复与姑息治疗专业委员会, 等. 肿瘤营养治疗通则[J]. 肿瘤代谢与营养电子杂志, 2016,3(1):28-33.
[66]	中华人民共和国卫生部. 癌症疼痛诊疗规范(2011年版)[J]. 中华危重症医学杂志: 电子版, 2012,17(1):153-158.
[67]	Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2020,38(14):1505-1517. DOI: 10.1200/JCO.19.03136. doi:10.1200/JCO.19.03136
[68]	Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung can-cer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013,143(5 Suppl):e211S-e250S. DOI: 10.1378/chest.12-2355. doi:10.1378/chest.12-2355
[69]	王洪武. 现代介入肺脏医学概况[J]. 国际呼吸杂志, 2012,32(4):269-274. DOI: 10.3760/cma.j.issn.1673-436X.2012.004.008.
[70]	北京健康促进会呼吸及肿瘤介入诊疗联盟. 恶性中心气道狭窄经支气管镜介入诊疗专家共识[J]. 中华肺部疾病杂志(电子版), 2017,10(6):647-654. DOI: 10.3877/cma.j.issn.1674-6902.2017.06.004.
[71]	Mudambi L, Miller R, Eapen GA. Malignant central airway obstruction[J]. J Thorac Dis, 2017,9(Suppl 10):S1087-S1110. DOI: 10.21037/jtd.2017.07.27. doi:10.21037/jtd
[72]	中华医学会呼吸病学分会. 良性中心气道狭窄经支气管镜介入诊治专家共识[J]. 中华结核和呼吸杂志, 2017,40(6):408-418. DOI: 10.3760/cma.j.issn.1001-0939.2017.06.004.
[73]	Zhang J, Wang T, Wang J, et al. Effect of three interventional bronchoscopic methods on tracheal stenosis and the formation of granulation tissues in dogs[J]. Chin Med J (Engl), 2010,123(5):621-627.
[74]	金发光, 刘伟, 殷凯生. 复杂中心气道狭窄的诊断及综合介入治疗现状[J]. 生物医学工程与临床, 2010,14(2):176-179. DOI: 10.3969/j.issn.1009-7090.2010.02.023.

山东省医学会肺癌多学科规范化诊疗指南

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献74

相关文章15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[3]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[4]	贺嘉慧, 胡钦勇.基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[5]	山东省医学会肺癌食管癌多学科联合委员会.山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[6]	李雄安, 颜艳艳.丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[7]	左小平, 刘晓川, 吴西强, 李周, 夏天, 刘国凤.老年早期肺癌患者经胸腔镜肺切除术后心律失常发生的危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(12): 711-716.
[8]	陈郁, 许华, 刘海, 陈士新.基于CT影像学特征的恶性肺纯磨玻璃结节患者病理分型预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(11): 655-660.
[9]	张万芳, 王尤, 苏晶, 陈刚, 周福祥.肺原发尤文肉瘤/原始神经外胚层瘤1例[J]. 国际肿瘤学杂志, 2023, 50(1): 62-64.
[10]	杨莎, 杨晓华, 王苏华, 薛晓燕, 徐俊.老年肺癌胸腔镜手术后下肢深静脉血栓的危险因素分析及预测模型的建立和验证[J]. 国际肿瘤学杂志, 2022, 49(9): 532-536.
[11]	王津, 张耀圣, 孙婷婷, 王丹, 胡乃东.以前胸壁聚集性多发蕈状肿物为表现的肺腺鳞状细胞癌皮肤转移1例[J]. 国际肿瘤学杂志, 2022, 49(9): 575-576.
[12]	陈煌婧, 朱鹏飞, 张晴, 陈桂芳, 杨春林, 何英.超声造影和CT引导下经皮穿刺活检在周围型肺肿块诊断中临床价值的比较[J]. 国际肿瘤学杂志, 2022, 49(8): 459-463.
[13]	蔡刚祥, 李境, 许斌.肺癌新辅助免疫治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 366-370.
[14]	韩丛丛, 付帅, 谢超, 张建军, 张秋景, 祝情情, 刘杰.吉非替尼、培美曲塞和贝伐珠单抗一线治疗EGFR突变晚期肺腺癌的有效性和安全性[J]. 国际肿瘤学杂志, 2022, 49(6): 376-379.
[15]	王永洪, 何弢, 李星, 罗启余, 王乔羽.信迪利单抗致晚期鳞状细胞肺癌患者致死性中毒性表皮坏死松解症1例[J]. 国际肿瘤学杂志, 2022, 49(6): 380-382.